Background Pulmonary sarcoidosis is a common condition with an unpredictable course.
Oral (OCS) or inhaled steroids (ICS) are widely used in its treatment, but there is no …

Corticosteroids (oral or inhaled) are commonly used to treat pulmonary sarcoidosis;
however, there is no consensus about when to start treatment, what dose of steroids to give …

ContextCorticosteroids are used in pulmonary sarcoidosis to reduce symptoms and
minimize long-term damage. Spontaneous recovery is a common feature. Both the decision …

Background Immunosuppressive and cytotoxic agents have been used as both an
alternative to oral corticosteroids, and as a means of maintaining a low dose of steroids in …

Pulmonary sarcoidosis presents substantial management challenges, with limited evidence
on effective therapies and phenotypes. In the absence of definitive evidence, expert …

BACKGROUND: Most issues concerning pharmacotherapy of pulmonary sarcoidosis have
not been resolved in clinical trials. The objective was to survey sarcoidosis experts …

Background Treatment of pulmonary sarcoidosis is recommended in case of significant
symptoms, impaired or deteriorating lung function. Evidence-based treatment …

Background Current guidelines recommend 20–40 mg· day− 1 of oral prednisolone for
treating pulmonary sarcoidosis. Whether the higher dose (40 mg· day− 1) can improve …

Background The major reasons to treat sarcoidosis are to lower the morbidity and mortality
risk or to improve quality of life (QoL). The indication for treatment varies depending on …

Sarcoidosis is a chronic, multiorgan disorder of unknown aetiology, characterized in affected
organs by an accumulation of T lymphocytes and mononuclear phagocytes, noncaseating …